Tag Archives: AstraZeneca

Highmark’s Strategy to Contain Drug Costs Includes an Increasing Number of Outcome-Based Contracts

Pharmaceutical manufacturers and payers have developed a number of agreements under which reimbursement is contingent on specific outcomes over the last few years

Onco360’s Pharmacy Network the Choice for New Oncology Treatments

Onco360, a subsidiary of PharMerica, is one of the nation’s leading providers of Oncology Pharmacy services

BrightInsight Growing its Number of Biopharma Partnerships

BrightInsight’s platform is designed for pharmaceutical and medtech companies that want their devices and drug-delivery systems to talk to each other and generate usable information

BMS Implementing Digital Therapeutics Strategy

BMS digital strategy has required thinking differently about the type of value-based relationships the company wants to establish

Highmark Develops Initiatives to Control Drug Spending

Highmark members will receive hemophilia drugs exclusively from three specialty pharmacies

Limited Distribution Networks

Limited Distribution Networks growth continues as Specialty Pharmacies compete to be chosen to distribute specialty pharmaceuticals. AMI’s report, Distribution Decision-Making for Specialty Drugs, found that Pharmaceutical manufacturers typically develop a product-specific distribution strategy dependent on company-specific criteria when bringing a new specialty drug to the market. Pharmaceutical manufacturers consider approximately 100-150 different specialty pharmacies (SPs) […]